| 12/01 | Surrozen: Targeted Regeneration Presentation |  |
| 05/01 | Surrozen, Inc./de: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or .. | |
| 04/01 | Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference | |
| 2022 | Top Premarket Decliners | |
| 2022 | Surrozen, Inc./de: Other Events (form 8-K) | |
| 2022 | Surrozen: Repurchase of Common Stock and Warrants to Purchase Common Stock - Form 8-K | |
| 2022 | Weaker-Than-Expected Retail Sales, Hawkish Fed Send US Stock Futures Sharply Lower | |
| 2022 | Tranche Update on Surrozen, Inc.'s Equity Buyback Plan announced on December 15, 2022. | |
| 2022 | Surrozen, Inc. announces an Equity Buyback for 1,310,496 shares, for $2.7 million. | |
| 2022 | Federal Reserve's Still-Hawkish Stance Appears to Disappoint Investors; US Futures Move.. | |
| 2022 | Top Premarket Gainers | |
| 2022 | Surrozen, Inc.'s Equity Buyback announced on December 15, 2022, has closed with 1,310,4.. | |
| 2022 | Surrozen Files $200 Million Mixed Shelf | |
| 2022 | Surrozen, Inc. authorizes a Buyback Plan. | |
| 2022 | Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopath.. | |
| 2022 | SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu.. | |
| 2022 | Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep.. | |
| 2022 | Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update | |
| 2022 | Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroente.. | |
| 2022 | Surrozen, Boehringer Ingelheim to Support Research, Development of Retinal Diseases Tre.. | |
| 2022 | Surrozen, Inc./de: Entry into a Material Definitive Agreement (form 8-K) | |
| 2022 | Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agoni.. | |
| 2022 | Surrozen, Inc. Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt.. | |
| 2022 | Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating t.. | |
| 2022 | Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating t.. | |
| 2022 | Surrozen: SZN-1326 13-week GLP Toxicity Studies | |
| 2022 | Surrozen: SZN-043 Hepatocyte Proliferation in 14-day daily dosing Edu-labeling study | |
| 2022 | SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu.. | |
| 2022 | Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Jun.. | |
| 2022 | Surrozen: Reports Second Quarter 2022 Financial Results - Form 8-K | |
| 2022 | Surrozen Reports Second Quarter 2022 Financial Results | |
| 2022 | Surrozen, Inc.(NasdaqCM:SRZN) added to Russell Microcap Value In.. | |
| 2022 | Surrozen, Inc.(NasdaqCM:SRZN) added to Russell 3000E Index | |
| 2022 | Surrozen, Inc.(NasdaqCM:SRZN) added to Russell Microcap Index | |
| 2022 | Surrozen, Inc.(NasdaqCM:SRZN) added to Russell 3000E Value Index | |
| 2022 | Surrozen, Inc./de: Submission of Matters to a Vote of Security Holders, Financial Stateme.. | |
| 2022 | Surrozen Doses First Patient in Early Trial of SZN-043 to Treat Alcoholic Hepatitis | |
| 2022 | Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hep.. | |
| 2022 | Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcohol.. | |
| 2022 | Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW) | |
| 2022 | Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week | |
| 2022 | Surrozen Begins Dosing in Phase 1 Study of Ulcerative Colitis Treatment; Shares Rise Ea.. | |
| 2022 | Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe .. | |
| 2022 | Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to S.. | |
| 2022 | Surrozen: SZN-043 Induced Quick and Robust Hepatocyte Proliferation in a 14-Day Daily Dos.. | |
| 2022 | Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology De.. | |
| 2022 | SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu.. | |
| 2022 | Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | |
| 2022 | Surrozen Reports First Quarter 2022 Financial Results | |
| 2022 | Surrozen to Present at the BofA Securities 2022 Healthcare Conference | |
| 2022 | Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Re.. | |
| 2022 | Surrozen, Inc. Presents Data Supporting Potential of SZN-413 for the Treatment of Diabe.. | |
| 2022 | Surrozen: Association for Research in Vision and Ophthalmology | |
| 2022 | SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu.. | |
| 2022 | Surrozen: Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K | |
| 2022 | Surrozen, Inc./de: Results of Operations and Financial Condition, Shareholder Director No.. | |
| 2022 | Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 | |
| 2022 | Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results | |
| 2022 | Surrozen, Inc./de: Entry into a Material Definitive Agreement, Unregistered Sale of Equit.. | |
| 2022 | Surrozen: Pep Talk 2022 Poster | |
| 2022 | Surrozen: Investor Presentation January 2022 | |
| 2022 | Surrozen, Inc./de: Other Events (form 8-K) | |
| 2022 | Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research P.. | |
| 2022 | Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference | |
| 2021 | Surrozen: Reports Third Quarter 2021 Financial Results - Form 8-K | |
| 2021 | Surrozen Reports Third Quarter 2021 Financial Results | |
| 2021 | Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference | |
| 2021 | Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference | |
| 2021 | Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the A.. | |
| 2021 | Surrozen, Inc. Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021,.. | |
| 2021 | Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference | |
| 2021 | Surrozen : Drug Candidate Shows Potential in Bowel Disease Based on Preclinical.. | |
| 2021 | Surrozen: Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gas.. | |
| 2021 | Surrozen: Announces Appointment of Liz Nguyen as Vice President and Head of Human Resourc.. | |
| 2021 | Surrozen, Inc. Announces Appointment of Liz Nguyen as Vice President and Head of Human .. | |
| 2021 | Surrozen, Inc.(NasdaqCM:SRZN) added to S&P TMI Index | |
| 2021 | Top Midday Gainers | |
| 2021 | Surrozen : Stock Jumps after Stifel Begins Coverage | |
| 2021 | Surrozen: Unaudited Condensed Interim Financial Statements for the Three and Six Months E.. | |
| 2021 | Consonance-HFW Acquisition Corp.(NasdaqCM:SRZN) add.. | |
| 2021 | Consonance Hfw Acquisition: Common stock and warrants to commence trading on Nasdaq on Au.. | |
| 2021 | Consonance Hfw Acquisition: Surrozen Debuts as Publicly Traded Leader in Wnt Biology and .. | |
| 2021 | Surrozen, Inc. announced that it has received $120.2 million in funding from Consonance.. | |
| 2021 | Surrozen, Inc. completed the acquisition of Consonance-HFW Acquisition Corp. from Conso.. | |
| 2021 | Consonance-Hfw Acquisition Corp. Reports Earnings Results for the Second Quarter Ended .. | |
| 2021 | Consonance Hfw Acquisition: Business Combination Agreement (Form 8-K) | |
| 2021 | Consonance Hfw Acquisition: New Surrozen to Trade on Nasdaq as "SRZN" (Form 8-K) | |
| 2021 | Consonance Hfw Acquisition: New Surrozen to Trade on Nasdaq as “SRZN” | |
| 2021 | Consonance-Hfw Acquisition Corp. Reports Earnings Results for the First Quarter Ended M.. | |
| 2021 | Certain Class B Ordinary Shares of Consonance-HFW Acquisition Corp. are subject to a Lo.. | |
| 2021 | Surrozen, Inc. Auditor Raises 'Going Concern' Doubt | |
| 2021 | Consonance HFW Acquisition : Surrozen Agrees to Merge With SP.. | |
| 2021 | Consonance Hfw Acquisition: Surrozen and Consonance-HFW Acquisition Corp. Announce Busine.. | |
| 2021 | Surrozen, Inc. announced that it expects to receive $120.2 million in funding from Cons.. | |
| 2021 | Surrozen, Inc. signed a definitive agreement to acquire Consonance-HFW Acquisition Corp.. | |
| 2020 | Consonance-HFW Acquisition Corp. announced that it has received $4.1 million in funding.. | |
| 2020 | Consonance-HFW Acquisition Corp. has completed an IPO in the amount of $80 million. | |
| 2020 | Consonance-HFW Acquisition Corp. has filed an IPO in the amount of $100 million. | |
| 2020 | Consonance-HFW Acquisition Corp. announced that it expects to receive $4.5 million in f.. | |
| 2016 | Surrozen, Inc. announced that it expects to receive $33.555555 million in funding | |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Nederlands (Nederland)
Nederlands (België)
Rapporto
